Research Progress of Targeting BCL-2 and MCL-1 in Relapsed/Refractory Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2025.03.045
- Author:
Qian-Ying MA
1
;
Zi-Xiu WEI
1
;
Juan CHENG
1
Author Information
1. The First Clinical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
- Publication Type:English Abstract
- Keywords:
relapsed/refractory;
acute myeloid leukemia;
MCL-1;
BCL-2;
targeting therapy
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Myeloid Cell Leukemia Sequence 1 Protein;
Proto-Oncogene Proteins c-bcl-2;
Drug Resistance, Neoplasm;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*;
Sulfonamides/therapeutic use*;
Recurrence
- From:
Journal of Experimental Hematology
2025;33(3):918-921
- CountryChina
- Language:Chinese
-
Abstract:
Poor prognosis and high mortality rate are frequently observed in patients with relapsed/refractory acute myeloid leukemia (R/R AML), and there is no standard salvage therapy for these patients. As a method to evade apoptosis, cancer cells often upregulate anti-apoptotic proteins BCL-2 and MCL-1. Recently, venetoclax-based combination therapies have demonstrated promising prospects in treating R/R AML. However, the prevalent use of venetoclax comes with a new challenge of resistance. Upregulation of BCL-1 and/or MCL-1 is the main cause of venetoclax resistance and preemptively targeting BCL-2/BCL-XL/MCL-1 can be used to delay or forestall drug resistance. Thus, selective targeting of BCL-2 and MCL-1 is a viable treatment strategy. This review reports the latest clinical progress on targeting BCL-2 and MCL-1 in R/R AML.
